Minimally invasive surgery for advanced ovarian cancer after chemo
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests whether doing surgery with small incisions (minimally invasive) instead of a large cut is safe and effective for advanced ovarian cancer after chemo. It may mean a faster recovery while still removing the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-grade ovarian, fallopian tube, or primary peritoneal cancer that is stage IIIC or IV.
- You've had at least 6 rounds of chemo before surgery, and scans show your belly cancer has shrunk or disappeared.
- Your CA125 blood level is below 100.
- You are able to carry out daily activities with little or no help (ECOG 0-1).
- A team of doctors reviewing your scans believes that surgery can be done with small incisions (minimally invasive) to remove all visible cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a minimally invasive surgery (laparoscopic debulking) can remove tumor in people with advanced epithelial ovarian cancer. It may help doctors compare whether this approach is safe and effective for patients who need either upfront surgery or surgery after chemotherapy.
This trial tests giving chemotherapy directly into the abdomen (intraperitoneal) after optimal surgery for advanced ovarian cancer. It aims to see if this approach is safe and effective for women who have already received 3-4 cycles of chemotherapy before surgery.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial is testing a combination of two new immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery and together with chemotherapy for advanced ovarian cancer. It aims to see if this approach can shrink the cancer more effectively and improve outcomes.
This trial is for people with recurrent ovarian cancer whose disease came back more than 6 months after platinum chemo. It tests whether removing the recurrent tumor with surgery (after more chemo) can help—even if surgery wasn't an option before.
This study looks at whether the timing of surgery after chemotherapy can be personalized for advanced ovarian cancer. It uses a blood test (CA125) to help decide the best time for surgery, aiming to improve outcomes.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.